3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
129
Melanoma
90
Squamous Cell Carcinoma of Head and Neck
88
Breast Neoplasms
70
Triple Negative Breast Neoplasms
64
Parkinson Disease 4, Autosomal Dominant Lewy Body
45
Head and Neck Neoplasms
45
Lung Neoplasms
38
Ovarian Neoplasms
37
Neoplasms
37
Neoplasm Metastasis
37
Colorectal Neoplasms
37
Stomach Neoplasms
36
Carcinoma, Renal Cell
34
Carcinoma, Transitional Cell
31
Pancreatic Neoplasms
29
Urinary Bladder Neoplasms
28
Carcinoma, Hepatocellular
27
Recurrence
21
Hodgkin Disease
21
Uterine Cervical Neoplasms
20
Endometrial Neoplasms
20
Prostatic Neoplasms
18
Esophageal Neoplasms
18
Sarcoma
17
Glioblastoma
17
Brain Neoplasms
16
Fallopian Tube Neoplasms
15
Esophageal Squamous Cell Carcinoma
15
Carcinoma, Squamous Cell
14
Interventions
tremelimumab
1
pembrolizumab
1
envafolimab
1
durvalumab
1
Paclitaxel
1
Endostatins
1
Drug Therapy
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Squamous Non-small Cell Lung Cancer
×
pembrolizumab
×
Clear all
NCT07221474
2026-05-28
INTerpath-13
Merck Sharp & Dohme LLC
Phase 2
Recruiting
180 enrolled